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Abstract
Background:
SARS-CoV-2 coronavirus infection ranges from asymptomatic through to fatal COVID-19 
characterised by a “cytokine storm” and lung failure. Vitamin D deficiency has been postulated as 
a determinant of severity.A
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Objectives:
To review the evidence relevant to vitamin D and COVID-19
Methods:
Narrative review
Results:
Regression modelling shows that more northerly countries in the Northern Hemisphere are 
currently (May 2020) showing relatively high COVID-19 mortality, with an estimated 4.4% 
increase in mortality for each 1 degree latitude north of 28 degrees North (P=0.031) after 
adjustment for age of population. This supports a role for ultraviolet B acting via vitamin D 
synthesis. Factors associated with worse COVID-19 prognosis include old age, ethnicity, male sex, 
obesity, diabetes and hypertension and these also associate with deficiency of vitamin D or its 
response. Vitamin D deficiency is also linked to severity of childhood respiratory illness. 
Experimentally, vitamin D increases the ratio of angiotensin converting enzyme 2 (ACE2) to ACE, 
thus increasing angiotensin II hydrolysis and reducing subsequent inflammatory cytokine 
response to pathogens and lung injury.  
Conclusions:
Substantial evidence supports a link between vitamin D deficiency and COVID-19 severity but it is 
all indirect. Community-based placebo-controlled trials of vitamin D supplementation may be 
difficult. Further evidence could come from study of COVID-19 outcomes in large cohorts with 
information on prescribing data for vitamin D supplementation or assay of serum unbound 
25(OH) vitamin D levels. Meanwhile vitamin D supplementation should be strongly advised for 
people likely to be deficient.
Keywords: 
vitamin D, COVID-19, cytokine
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Introduction
The SARS-CoV-2 coronavirus is an enveloped RNA virus, infection by which provokes a 
remarkable range of responses from complete lack of symptoms through to cytokine storm and 
life-threatening Acute Respiratory Distress Syndrome (ARDS) [1,2]. The explanations for this 
extremely variable prognosis are unclear. Mortality from coronavirus infectious disease 2019 
(COVID-19) is higher amongst people who are older, male, obese, diabetic, hypertensive, or who 
are from black, Asian, or minority ethnic (BAME) demographics. All these factors are associated 
with increased prevalence of vitamin D deficiency or, as in male sex, with reduced impact of 
vitamin D on the immune response.  Vitamin D is, like cortisone and sex hormones, a cholesterol-
derived steroid hormone and it modulates expression of around 5% of human genes including 
many relevant to the immune response to pathogens.  We have therefore examined the 
evidence that vitamin D deficiency might be a factor determining severity of COVID-19. 
Association between northerly latitude and increased mortality from COVID-19
There is currently (May 2020) a significant association between northerly latitude and mortality 
from COVID-19 expressed per million population across the 117 countries with more than 1 
million population and more than 150 recorded cases at time of sampling (Figure 1) [3]. Much of 
this association is due to the younger age of populations in some countries. Adjusting for per 
cent of population ≥65 years does however leave a significant relationship between latitude and 
COVID-19 mortality (P=0.031) with an estimated 4.4% increase in mortality for each 1 degree 
latitude north of 28 degrees North (Table 1). Addition of neither pollution (particles of matter 
<2.5um diameter (PM2.5) micrograms/m3) nor population density per country added significant 
explanatory power to a model containing latitude and age. An association between Northerly 
latitude and mortality has also been noted amongst African-Americans across the USA [4]
Associations between COVID-19 mortality and latitude suggest a possible effect of ultraviolet 
light. A substantial source of vitamin D comes from synthesis in the skin from its precursor 7-
dehydrocholesterol as a consequence of ultraviolet light (UVB) exposure. People living far from 
the equator may therefore become vitamin D deficient in the winter and spring, with levels 
lowest from December to May [5]. It is estimated that at latitudes below 35 degrees either side A
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of the equator UVB radiation is sufficient for year-round vitamin D synthesis, although this will 
also depend on diet, skin colour, clothing, time spent outdoors, and use of sun-screen [6]. 
Interpretation of country to country variation is further complicated by variable approaches to 
supplementation and vitamin D food fortification initiatives. Thus, vitamin D levels are generally 
well maintained despite relative lack of UVB exposure in Nordic countries due to widespread use 
of supplements and food fortification whereas deficiency is commoner in the United Kingdom 
and in southern European countries, [7,8] and particularly amongst persons over 80 years and 
those in institutions. We have recently reported a significant correlation between COVID-19 
mortality and reported average serum vitamin D levels across European countries [9]. Vitamin D 
deficiency defined as <30nmol/l is found in over 10% of Europeans [7] but it has been suggested 
that a level of at least 50nmol/l may be optimal [6]. Wuhan itself, where the outbreak started, is 
at latitude 31 degrees north however air pollution is also a major factor limiting UVB radiation 
and has previously been very marked over this densely populated (11M) city [10]. There are 
currently no population-based vitamin D data available from Wuhan. In sunnier Brazil, whose 
capital Brasilia is at -16 degrees latitude, there is now high mortality but meta-analysis has shown 
28% prevalence of vitamin D deficiency [11]. 
Alternative explanations for the north-south gradient in COVID-19 mortality are arguably less 
plausible. Although population density expressed per country does not currently associate with 
COVID-19 mortality it could be speculated that cities tend to be smaller and urban populations 
less densely crowded further south but there are many examples of high population cities below 
28 degrees latitude north– Karachi 14.9M, Hong Kong 7.4M, Mexico City 8.9M, Nairobi 4.3M, 
Sidney 5.2M for example. It can also be pointed out that there is a north-south gradient for 
diagnosed cases, however, if true – for diagnosis rate is of course very dependent on testing 
frequency - this may well reflect the longer period of infectivity that is associated with more 
severe COVID-19 illness. It does not seem very likely that the virus has simply had less 
opportunity to spread south of the equator given that we are now 4 months into the pandemic. 
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Ultraviolet light, particularly UVB, has also been shown to have direct immunosuppressive effects 
on the skin, that include suppression of contact sensitivity at the UV-irradiated site and induction 
of antigen-specific tolerance mediated by regulatory T lymphocytes. Significant systemic 
immunosuppression has also been demonstrated in experimental models [12]. Various 
mediators are thought to be responsible for these effects. These include cis-urocanic acid, 
generated by the isomerization of trans-urocanic acid, which binds to the serotonin receptor on 
antigen presenting cells, keratinocytes and mast cells; also cyclobutene pyrimidine dimers, 
generated by UV-mediated nucleotide damage, and oxidation products of membrane lipids. 
UV light could also reduce viability of free virus in the environment. Although UVC light (200-
280nm wavelength) that has a strong germicidal effect does not penetrate the earth’s 
atmosphere,  UVB (280 to 320nm) has a weaker but significant anti-viral effect that may shorten 
the survival of the virus on surfaces and thus reduce  infection rates [13]. Higher temperature 
and higher humidity can also decrease viral survival in the environment and have been shown to 
correlate with reduced COVID-19 infection rates and mortality across 166 countries [14]. The 
evidence is contradictory though: a recent study in the USA has linked UVB, and higher 
temperature, but not rainfall with lower SARS-CoV-2 infection rates [15] whereas a study across 
Chinese cities has shown no association with either UVB or temperature and R0 or infection rates 
[16]. 
Thus, although the association with latitude implies that COVID-19 may prove seasonal, the 
mechanisms underlying this could include any or all of: impacts of UVB on the immune system 
mediated by vitamin D synthesis, other consequences of the actions of UVB in the skin, and 
direct effects on environmental survival of SARS-CoV-2 consequent to UVB, humidity, or 
temperature. Of these, only an effect of UVB mediated by vitamin D synthesis would readily 
explain the associations between COVID-19 mortality and ethnicity.
Vitamin D chemistry and biology 
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Vitamin D, uniquely amongst the vitamins, is a steroid hormone. It is fat-soluble and exists in two 
forms, vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Both are generated by the 
action of UVB, splitting a single (9,10) carbon-carbon bond in their respective precursors – 
ergosterol and cholesterol thus generating a secosteroid or “cut” steroid. Ergosterol is the 
precursor in fungi and plankton and cholesterol the precursor in animals. The chemical structure 
of vitamin D therefore has close similarities with that of the other cholesterol-derived hormones 
such as cortisol, aldosterone, testosterone and oestrogen (Figure 2). Vitamin D3 has greater 
affinity for the circulating vitamin D binding protein and a substantially longer half-life in the 
circulation than vitamin D2 [18]. This is probably only of major significance if taken by 
intermittent bolus dosing rather than daily supplementation [19]. After the generation of 
cholecalciferol (or ergocalciferol) further hydroxylation is required in the liver and then the 
kidney to generate the active 1,25 dihydroxycholecalciferol. It should be noted though that 
macrophages/dendritic cells also have the ability to convert 25(OH)D to 1,25(OH)2D via CYP27B1 
and that clinical consequences of vitamin D deficiency correlate better with serum concentration 
of 25(OH)D rather than with the (1000-fold lower) serum concentration of  1,25(OH)2D [20]. 
Although lymphocytes also express CYP27B1 this is at substantially lower level and the regulatory 
(anti-inflammatory) effect of vitamin D on human lymphocytes in mixed cell culture requires the 
presence of antigen-presenting dendritic cells [21]. The daily requirement of vitamin D is 
estimated at between 5 and 20 micrograms (200 to 800IU) [6] and it is not easy to achieve this 
through diet alone. Oily fish is the only really substantial natural dietary source though farmed 
versus wild fish concentrations vary. Liver and eggs also contain vitamin D but a single egg only 
provides about 5% of the daily requirement. Mushrooms need to be subjected to UV irradiation 
and even then will only provide modest amounts of vitamin D2. For the majority of people the 
main source of vitamin D is its generation by the action of UVB on cholesterol in the skin. This is 
evidenced by the fact that in the UK blood levels of vitamin D are approximately 50% lower in 
February than in September [22]. (Figure 2) That seasonal differences are not even greater 
reflects the long half-life of vitamin D in the body (2-3 months), predominantly in fat stores, in 
contrast to its relatively short half-life in the blood (2-3 weeks) [23]. 
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Vitamin D is best known for its effects on calcium and phosphate absorption, osteoclast 
activation, and hence on bone calcification and muscle strength [24]. However, the vitamin D 
receptor is very widely expressed, including by all leucocyte classes [25]. 
In the blood approximately 85% of vitamin D is bound to vitamin D binding protein (DBP), 15% to 
albumin and just 0.03% of 25(OH)D3 and 0.4% of total 1,25(OH)2D3 are free vitamin D [26]. It is 
thought that in most cells only free vitamin D can enter the cell. Cellular entry by protein-bound 
vitamin D is dependent on expression of the cell surface receptor proteins megalin and cubulin 
[20] and is largely restricted to the kidney, parathyroid and placenta. Free vitamin D diffuses 
through the plasma membrane and binds to the vitamin D receptor (VDR) in the cell nucleus 
where the vitamin D/VDR complex then interacts with vitamin D response elements in the 
genome. It is estimated that vitamin D affects the transcription of around 1000 genes ie around 
5% of the human genome [27]. In pooled leucocytes it has been shown that at least 60 genes are 
vitamin D-responsive [28] and nearly two hundred genes in monocyte/macrophage cells [29-31]. 
(Figure 2) Vitamin D therefore has substantial effects on the immune system that are highly 
relevant to the response to pathogens.
Impact of vitamin D on immunological response to pathogens – clinical studies
A protective effect of cod-liver oil in tuberculosis was recognised in an early therapeutic trial 
conducted at London’s Brompton hospital in the 1840’s [32] and the role of vitamin D in this 
effect was recognised in the 1940’s, initially with the successful treatment of cutaneous 
tuberculosis, and subsequently with many confirmatory studies [33]. Since then knowledge of 
the impacts of vitamin D on the immune system has expanded greatly and there has been 
increasing recent focus into its role in determining response to viral infections, particularly 
respiratory viruses. 
The evidence both from laboratory studies and from clinical studies is that vitamin D status has 
probably only a small impact on risk for viral infection but a much more important impact on 
inflammatory response and hence severity. Thus, a meta-analysis looking at impact of 
supplementary vitamin D on risk for upper respiratory tract infection showed a statistically A
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significant but very modest reduction, from 42.2% to 40.3%, in risk of one or more infections 
[34]. However, amongst those who were vitamin D deficient at baseline the reduction in 
infection rate was greater – from 55.0% down to 40.5%. A beneficial effect was only seen with 
regular daily dosing and not with intermittent bolus dosing.  Probably more impressive is the 
association between vitamin D deficiency and severity of respiratory disease – for example the 
need for intensive care in 1016 infants hospitalized with bronchiolitis (22% if vitamin D <20ng/ml 
(50 nmol/l), compared with 12% if vitamin D >30 ng/ml (75 nmol/l); P=0.003) [35]. 
A study in Irish people >60 years old and healthy apart from hypertension showed a strong 
correlation between vitamin D deficiency and increase in both IL-6 and C reactive protein [36]. A 
detailed investigation of the impacts of vitamin D, gender and seasonality on cytokines has 
subsequently been undertaken in 534 healthy subjects as part of the Human Functional 
Genomics Project [37]. This showed that monocyte inflammatory cytokine responses to 
lipolysaccharide and Candida albicans are substantially greater in men. Several inflammatory 
cytokines, including TNFalpha, Interleukin beta and Interleukin 6 were shown to be higher in 
summer, mostly showing no relationship with vitamin D. 
Interpreting serum vitamin D levels during illness – the negative acute phase effect
Studies of vitamin D levels in individuals who are already ill or have raised inflammatory markers 
have to be interpreted with caution. Controlled studies in calves infected with bovine diarrhoea 
virus (BVDV) showed that serum vitamin D levels fell by 57% during the acute phase response to 
illness [38] and similar falls have been documented in humans following orthopaedic surgery and 
acute pancreatitis [39].  Both serum vitamin D binding protein (DBP) and albumin concentrations 
fall in illness and total vitamin D levels will fall as a consequence. It is therefore almost inevitable 
that there will be a correlation between lower total serum vitamin D levels and increased COVID-
19 severity. There are several possible ways of getting around this problem:
(i) Measurement of free vitamin DA
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Total 25(OH)D serum concentration in serum is generally acknowledged to be the de facto 
biomarker of vitamin D status. However, as already noted, the unbound (i.e. free) concentration 
of 25(OH)D is below 0.5% of the total concentration [26,40]. Emerging evidence points to a 
critical role for free, rather than total 25(OH)D in mediating important cellular processes related 
to immunity. For instance, in vitro studies have demonstrated reduced immune functions of 
dendritic cells [21] and adherent monocytes [41] by increasing DBP in culture media which 
reduces the amount of free 25 (OH)D. This is analogous to free thyroid hormones or testosterone 
which are physiologically more relevant than their total concentration.  
Measurement of free 25(OH)D has been challenging due to its very low serum concentrations 
(approximately 10 fold less than free thyroid hormones) and has historically relied on 
cumbersome radioactive tracer based methods [42]. More recently, two further assays, including 
an ELISA [43] and a high throughput mass spectrometric method [44] for direct measurement of 
free 25(OH)D have been introduced, but require further clinical and technical validation. Thus, 
computational methods which rely on concentrations of total ligands and DBP and their in vitro 
measured affinity constant are often used to calculate free 25(OH)D [45].  It is important to note, 
however, that the biological significance of DBP’s various allelic forms on DBP concentrations  
and affinity differences is yet to be fully established. The experimentally measured affinity 
differences for vitamin D metabolites for various genotypic forms of DBP, with the exception of 
one study [46] appear to be small [47,48]. On the other hand, genotype has been consistently 
shown to alter serum DBP concentrations [49,50]. In summary, the main role of DBP in 
determining free 25(OH)D levels appear to be DBP concentration dependent rather than 
genotype dependent.  Thus, measurement of serum DBP and albumin alongside total 25(OH)D 
should allow a robust computational approach for calculating free 25(OH)D and permit a better  
correlation between vitamin D status and COVID-19 severity.
(ii) Associations with vitamin D receptor polymorphism
Vitamin D receptor polymorphisms impact on vitamin D response.  Meta-analysis has shown a 
highly significant relationship (p=0.007 OR 1.52) between hospitalisation for Respiratory Syncytial 
Virus (RSV) bronchiolitis and possession of a minor allele for a vitamin D receptor polymorphism 
(Fok1-f rs2228570) that lowers transcriptional activity of the vitamin D receptor [51]. This A
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polymorphism has an allele frequency of 13 to 38% in healthy subjects so it could be very 
informative to know whether this allele is also seen with higher frequency in people with more 
severe COVID-19. 
(iii) Mendelian randomisation
The difficulty in interpreting serum vitamin D levels during illness has led investigators to 
consider the application of Mendelian randomisation. This uses gene polymorphisms that predict 
vitamin D status as a surrogate for vitamin D deficiency. One approach that has proved successful 
has used gene polymorphisms associated with risk of skin colour, tanning, or freckling. This 
identified a group of gene polymorphisms that together were predictive of vitamin D status [52]. 
However, this included genes such as HERC2 that are major determinants of blue eye colour [53] 
which in turn are strongly associated with reduced pigmentation and enhanced vitamin D 
response to UVB in white individuals [54]. This approach may therefore be less effective in a 
population that contains mixed ethnicities. 
A broader statistical approach is to use a genome wide-association study (GWAS) to identify, in a 
hypothesis-free fashion, polymorphisms that associate with vitamin D deficiency.  This has been 
done in a remarkable study across 79,366 European-ancestry individuals [55]. Polymorphisms at 
six loci were informative with high significance. However, the overall estimate of heritability of 
serum vitamin D concentrations was found to be only 7.5% and with only 38% of that heritability 
accounted for by the identified polymorphisms. This approach will therefore only be useable 
with very large sample sizes. Moreover, a different GWAS would need to be performed for other 
ethnic groups.
(iv) Measurement of vitamin D in hair or other tissues
Study of vitamin D levels in hair samples has been proposed as a way of avoiding the negative 
acute phase response effect of severe illness on serum vitamin D levels [56]. This approach is 
proving reliable in measurement of other steroid hormones such as cortisol [57,58] but would 
need further validation. A
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Impact of vitamin D on immunological response to pathogens – laboratory studies
In keeping with the clinical studies, experimental evidence shows that vitamin D has shown only 
inconsistent effects on viral replication in human respiratory epithelial cell culture but markedly 
down-regulates production of pro-inflammatory cytokines including TNFalpha and IL-6 by various 
mechanisms including inhibition of viral-induced NF-kappaB activation [59]. 
Vitamin D receptors are also expressed by most immune cells including activated T-cells B-cells 
and dendritic cells, and macrophages. Vitamin D is important for killing of phagocytosed bacteria, 
including Mycobacterium tuberculosis [60,61] and E. coli, [62] by macrophages. An important 
part of this bactericidal effect relates to the induction by vitamin D of cathelicidin, a cationic 
bactericidal peptide [63].  Cathelicidin (LL-37) can be produced not only by macrophages but also 
by epithelial cells and has been shown to have anti-viral activity, particularly against enveloped 
viruses [64]. Vitamin D has been shown to induce an antiviral effect against rhinovirus in cultured 
respiratory epithelial cells [65], an effect that can also be demonstrated by addition of exogenous 
cathelicidin [66]. An effect of cathelicidin against influenza has also been shown [67]. Currently 
though, the impacts of vitamin D on macrophage defence against viral pathogens have 
demonstrated a predominant impact on cytokine response rather than on viral killing [68]. Some 
of the work has focussed on Dengue fever, a viral infection that is well known for its very marked 
cytokine activation and risk of organ failure [69,70]. Vitamin D deficiency has been shown to 
correlate with increased risk of septic shock in patients with Dengue fever [71]. Experiments have 
shown consistent suppression of inflammatory cytokine response to pathogens by vitamin D, in 
macrophages, and also in T-cells and in various animal models of pneumonia and pneumonitis 
[72-74]. Cytokines suppressed include IL-6 that has been incriminated in COVID-19-associated 
ARDS. 
Given that vitamin D may regulate the response of nearly two hundred genes in the 
monocyte/macrophage it is not surprising that its suppressive effect on macrophage cytokine 
responsiveness has been shown to be effected via more than one pathway. Vitamin D has been 
shown to regulate the production of inflammatory signalling mediated by both NF-kappaB and 
STAT-1 [75] with MAPkinase activation as an important precursor [72]. There has therefore been A
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increasing speculation that vitamin D deficiency could contribute to a risk of more serious COVID-
19 disease with increased risk of cytokine storm and consequent Acute Respiratory Distress 
Syndrome (ARDS) [76,77].
Vitamin D immune response and gender
The impact of vitamin D on suppressing the immune response has been shown to differ between 
men and women. Vitamin D induces reduction in pro-inflammatory cytokines IL17 and interferon 
gamma and increase of interleukin10 production by CD4+ T lymphocytes, effects that are much 
greater in T lymphocytes from women than from men. Similarly, antiCD3 and anti-CD28-
stimulated peripheral blood mononuclear cells from men generated less than half the number of 
regulatory CD4+CD25+FoxP3+ T lymphocytes in response to vitamin D compared with cells from 
women, but this gender difference disappeared when estradiol was added [78]. In keeping with 
this a Norwegian study has looked at the effect of weekly supplementation with 20,000 IU 
vitamin D3 or placebo on the human transcriptome in pre-diabetic individuals with impaired 
glucose tolerance. Fifty-eight genes were shown to be significantly affected by vitamin D in men 
compared with 185 in women (P<0.05). In women 51 genes showed a 2-log difference in 
expression compared with only a single gene in men [79]. Genes affected included those related 
to the interleukin signalling pathway and B cell mediated immunity. The authors speculated that 
the gender difference might be related to oestrogen-dependent effects on synthesis of the 
vitamin D binding protein.
Increased prevalence of vitamin D deficiency amongst people with risk factors for severe 
COVID-19 including ethnicity, diabetes, hypertension, obesity and institutionalisation
Vitamin D deficiency is commoner in obese individuals, people with Type 2 diabetes, 
hypertension, and most strikingly amongst ethnic minorities in Europe and North America – 
where darker skin pigmentation reduces skin synthesis and eight-fold increased prevalence of 
deficiency is reported (Table 2) [80-83]. All of these are demographics that have been associated 
with increased risk of severe COVID-19. Vitamin D deficiency is also substantially commoner 
amongst people who are institutionalised including prisoners and people in care homes [84-87]. 
Since vitamin D is fat-soluble, its deficiency is also more likely in people with chronic digestive A
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disorders such as Crohn’s disease or chronic pancreatitis but, hopefully, most will be receiving 
supplements.
Vitamin D, the renin-angiotensin system, and COVID-19
The receptor for SARS-CoV-2, as for SARS-CoV, is angiotensin-converting enzyme 2 (ACE2) so 
there is intense interest in factors that alter its expression or function. ACE2 has potentially 
contradictory roles. Given that it is the receptor for SARS-CoV-2 it would be reasonable to 
assume that greater expression of ACE2 would be bad for the human host. However, since the 
discovery of ACE2 twenty years ago various studies have shown that it has a crucial role in 
protecting against acute lung injury and ARDS in experimental models [88-90]. The balance 
between ACE2 and ACE seems crucial as ACE2 counteracts the effects of ACE by hydrolysing 
angiotensin II to angiotensin(1-7). Since angiotensin II is central to the development of ARDS this 
is a very important protective mechanism.  So, more ACE2 is good – at least in respect of 
reducing risk of ARDS, and ACE2 also has a protective role against cardiovascular diseases 
[91,92]. ACE2 is highly expressed on human lung alveolar cells but also on vascular endothelial 
cells, smooth muscle cells, renal tubular epithelium, and small intestinal enterocytes. There is 
frustratingly little published information on its expression, or perhaps more importantly on the 
ratio of ACE2:ACE expression, in children, males, elderly, varying ethnicity etc other than very 
small human studies [93] or animal studies. The gene encoding ACE2 is carried on the X 
chromosome. Serum assays have shown no sex differences in ACE2 concentration overall but 
higher serum ACE2 in older women [94]. Studies in rats have however shown substantially 
reduced ACE2 expression with aging and particularly in older males [95].
Vitamin D has been shown experimentally to increase ACE2, reduce ACE expression, reduce 
angiotensin II production and reduce damage in lipopolysaccharide (lps)-induced lung injury in 
rats [96]. Similarly, vitamin D receptor gene knockout mice show much more severe acute lung 
injury and increased mortality in an lps-sepsis model of ARDS with amelioration by antagonists of 
angiotensin II [73]. Vitamin D also suppresses expression of renin, the rate-limiting enzyme in the 
renin-angiotensin cascade [97]. These effects are clearly highly relevant to a potential role of 
vitamin D in protecting against ARDS in COVID-19.A
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Vitamin D deficiency, lupus anticoagulant-associated thrombosis, and COVID-19 
Venous and arterial thrombo-embolic events are common in severe COVID-19, affecting 28% of 
cases admitted to intensive care, despite thromboprophylaxis, in an Italian case series of 388 
patients [98]. There has been considerable interest in the effects of vitamin D on coagulation but 
large studies have failed to show an impact of vitamin D status or supplementation on the risks 
for cardiovascular disease or thromboembolism [99,100].
A much stronger case can be made though for a protective effect of vitamin D against thrombotic 
complications of the anti-phospholipid syndrome, [101] and here there are intriguing parallels 
with the thrombotic tendency in COVID-19 [102]. Studies have shown a prevalence of up to 70% 
for vitamin D deficiency amongst patients with anti-phospholipid syndrome and meta-analysis of 
4 case-control studies including 325 cases and 507 controls showed an odds ratio of 3.06 
(P<0.001) for frequency of vitamin D deficiency in patients with anti-phospholipid syndrome 
[103]. In keeping with an effect of vitamin D, marked seasonality has been shown for 
antiphospholipid antibody titres in healthy controls with lower levels in summer months [104]. 
A systematic investigation of 56 patients hospitalised for COVID-19 found 25 (45%) positive for 
lupus anticoagulant on the basis of coagulation tests (dilute Russel’s viper venom time (DRVVT) 
and activated partial thromboplastin time (aPTT) although anticardiolipin or anti-beta2-
glycoprotein antibodies were only detected in 10% [105]. Another study reported that 20% of 
216 patients positive for SARS-CoV-2 were found to have a prolonged activated partial 
thromboplastin time (aPTT) and when most of these were further tested 91% were positive on 
lupus anticoagulant assay [106]. It is well recognised that lupus anticoagulant activity may 
develop transiently, typically for two to three months, in other viral infections [107].
Seasonal variation of vitamin D deficiency and implications for the COVID-19 pandemic
In the absence of vitamin D supplementation there is marked seasonal variation in vitamin D 
levels. In the UK for example sunlight does not contain sufficient UVB to allow skin vitamin D 
synthesis until April and in northern Europe blood levels in non-supplemented individuals may 
not rise substantially until late May or June [6]. Similarly, because of its relatively long half-life in A
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fat stores of 2-3 months, levels in the Southern Hemisphere typically do not drop until June. 
Moreover, older people and people with dark skin have much lower dermal synthesis of vitamin 
D in response to UVB [108]. The seasonality of respiratory virus infections is of course very well 
documented  for influenza, human coronavirus and Respiratory Syncytial Virus (RSV) – the 
“winter viruses” [109], although other factors such as temperature and humidity are likely also to 
underlie this. There is sound evidence linking vitamin D deficiency with risk for or severity of 
influenza [76,110] and RSV [51,75]. If COVID-19 severity is strongly related to vitamin D status 
this too may prove to be a winter virus, since more severe COVID-19 illness probably results in a 
longer period of infectivity. Current lock-down measures could of course blunt the normal 
summer rise in vitamin D.
Vitamin D in the COVID-19 pandemic – current knowledge
There are very limited peer-reviewed studies currently published and the current data are “soft”. 
The simplest but possibly the most informative is a questionnaire-based study in Italian patients 
with Parkinson’s disease (n=1486) and their family members (“controls” n= 1207) [111]. One 
hundred and five (7.1%) of patients and 92 (7.6%) family members had confirmed or probable 
COVID-19. Vitamin D supplements had been taken by 13/105 (12.4%) COVID-19 cases compared 
with 316/1381 (22.9%) unaffected – after age adjustment OR 0.56 (95%CI 0.32-0.99; P=0.048) for 
vitamin D supplements reducing odds of COVID-19 infection. 
Another study from Italy has reported serum vitamin D levels taken with 7 weeks of SARS-CoV-2 
PCR testing – mostly with 3 days of test [112]. Amongst 107 patients with available data, the 27 
SARS-CoV-2 positives had median 25(OH)D 11.1 ng/ml (IQR 8.2 – 21.0) compared with the 80 
SRS-CoV-2 negatives who had median 25(OH)D 24.6 ng/ml (IQR 8.9 – 30.5) (P=0.004). Because of 
the proximity of vitamin D assay to PCR testing it is possible that vitamin D levels could have 
been lowered as a consequence of a negative acute phase response. 
It should be noted that both of these studies are looking at the possible impact of vitamin D on 
risk for infection. No peer-reviewed studies have yet been published looking at possible impacts 
of vitamin D on COVID-19 severity.A
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Several pre-prints that have not yet undergone peer-review are available on-line but some of 
these are problematic. One of the more complete studies reports a retrospective cohort from 
Chicago of 4,314 patients tested for COVID-19 all of whom had a vitamin D level in the year 
before testing [113]. In multivariate analysis that adjusted for age and ethnicity, being likely 
vitamin D deficient (previous deficient level and lack of increased treatment) increased risk of 
testing positive for COVID-19 (RR 1.77, P<0.02). It should again be noted that this addresses 
whether vitamin D impacts on risk for infection but does not inform about risk of COVID-19 
severity.
Three studies, two currently on-line as pre-prints and one peer reviewed, have used historical 
vitamin D levels, measured between 2006-2010 in individuals sampled for the UK Biobank. These 
studies have shown no association between historical vitamin D levels (season-adjusted) and 
testing positive for COVID-19 but have not assessed COVID-19 severity [114-6]. 
Studies are urgently needed that examine COVID-19 outcomes in relation to vitamin D status or 
supplementation. An additional problem that needs addressing is possible confounding by a 
“healthy user” effect ie people with higher vitamin D levels possibly leading a healthier lifestyle 
in other ways. Care should be taken to adjust for relevant confounders such as deprivation, 
smoking and exercise.
Implications for current guidance
Many countries have recommendations for use of vitamin D supplements. Current UK guidance 
at https://www.nhs.uk/news/food-and-diet/the-new-guidelines-on-vitamin-d-what-you-need-to-
know/   is that “adults and children over the age of one should have 10 micrograms (400 
International units [IU]) of vitamin D every day. This means that some people may want to 
consider taking a supplement.” Recommendations from other countries vary and the World 
Health Organization recommends a daily intake of 5 micrograms (200IU) for adults but rising to 
15 micrograms (600IU) over 65 years [6]. The proportion of the population taking supplements is 
largely unknown although in one Irish study only 4% of men and 15% of women over 50 regularly 
took supplements [87].A
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The relevant advisory bodies: European Food Standards Agency, UK Scientific Advisory 
Committee on Nutrition, and US Institute of Medicine all consider an upper intake limit of 4000 
IU/day in adults [7]. The consensus recommendations for vitamin D intakes for older adults or 
those with little sun exposure (household or confined) is a daily intake of 10-20 micrograms (400-
800IU/day). Due to an inadequate dietary intake and lack of mandatory fortification in Europe 
and the United Kingdom a vitamin D supplement may be required to achieve this. However, 
lifestyle and demographic factors also need to be taken into account and the “one size fits all” 
will not achieve sufficient blood 25(OH)D concentrations across all people in a similar timeframe. 
For instance the response to vitamin D supplementation is blunted in those who are overweight 
or obese [117-20]. Furthermore, men possibly have a lower response to supplementation than 
women [117] and people with intestinal inflammatory conditions such as Crohn’s disease have 
poorer absorption. Baseline vitamin D status is also critical and older adults may have a lower 
response [121]. Consequently those with very low vitamin D concentrations, obesity, chronic 
intestinal disease or other conditions that affect vitamin D metabolism require either a much 
longer run-in time period of supplementation or a higher dose to reach a sufficient level in the 
same timeframe. 
Identification of appropriate supplementation dose depends on the target serum 25(OH)D 
concentration. Although >25 or 30 nmol/l is generally accepted as adequate for musculoskeletal 
health, it is recommended by the US Institute of Medicine that a higher level, >50 nmol/l, should 
be achieved [118]. Some authorities would recommend a still higher target level of >75nmol/l, 
but this is controversial. Extrapolation from a large number of cohort studies suggests that for 
adults, supplementation with 1000IU/day should be adequate, even in obese individuals, for 
achieving >50 nmol/l. However, to achieve >75 nmol/l would typically require supplementation 
of between 3000IU/day to 4000IU/day for an obese individual [118].
Finally, consideration also needs to be given to other dietary components that are required for 
vitamin D metabolism/function. For instance, the metabolism of vitamin D into the active form is 
a magnesium-dependent process while it also acts a co-factor for vitamin D binding protein A
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[122]. Dietary intakes of magnesium have been highlighted as low both in the US and UK 
populations [123-4]and the recommended intakes are around 420 mg/day for men and 
320mg/day for women [125].  
Implications for research
Research should include urgent observational studies comparing blood levels of vitamin D in the 
population with subsequent outcomes in COVID-19 illness but the caveat that vitamin D levels 
may fall during the acute phase response of a pyrexial illness may make interpretation difficult.  
Assay of free vitamin D may largely get around this problem. Simple observational studies of 
associations between prior vitamin D supplementation and COVID-19 outcomes could be the 
fastest route to useful evidence.
Randomised controlled trials are regarded as the “gold standard” for evidence but are probably 
harder to conduct when the intervention under test is an established vitamin rather than the 
more usual trial of a novel and potentially riskier drug. There are currently eleven clinical trials of 
vitamin D in COVID-19 registered on clintrials.gov (Table 3). Nine of these are in symptomatic 
patients. Supplementing vitamin D in people who are already ill might be too late to be effective, 
although certainly worthy of study. Two studies will address prophylaxis, one in people >60 who 
are institutionalised (Lille), and the other in health care workers and relatives of affected patients 
(Tehran).  Results from some of these studies will hopefully become available over the next few 
months. 
Conclusions
Urgent research is needed to assess whether vitamin D deficiency is associated with increased 
COVID-19 severity and to determine the effects of vitamin D supplementation. Meanwhile, given 
the strong circumstantial and biological evidence, and the relative safety of vitamin D 
supplementation, it seems sensible to advocate its use more widely during this pandemic, 
particularly for all those people at risk of vitamin D deficiency.  The potential gain if the 
hypothesis is correct would be massive.A
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These points are summarised in Table 4.
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1. Associations between COVID-19 mortality by country, latitude, and % of population ≥65 
years (from [3], data accessed 18th May 2020).
2. Associations between vitamin D status and demographic variables associated with COVID-
19 mortality
3. Trials of vitamin D in COVID-19 registered on clintrials.gov (12 June20)
4. Summary 
Legends to Figures:
1A. COVID-19 mortality per 1 million population by country compared with latitude of capital 
cities. Fitted values are derived from a piecewise linear model of the logarithm of mortality on 
latitude. This was based on a threshold of 28 degrees North that explained the greatest amount 
of variation.
1B. Logarithm of COVID-19 mortality per 1 million compared with latitude with and without 
adjustment for age (%≥65 years). Reproduced from [3] with permission. 
2A. Synthesis of vitamin D, adrenal and sex hormones from cholesterol. Adapted from 
Muscogiuri et al [17] with permission.
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2B. Seasonal variation in serum vitamin D levels (mean[95%CI]) amongst 7437 white British (1958 
British birth cohort) at age 45. Dark bar = male, pale bar = female. From Hypponen and Power 
[22] with permission.
2C. Heatmaps of vitamin D responsive genes in mixed leucocytes from individuals before and 
after 2 months of vitamin D supplementation. Four individuals had prior vitamin D deficiency and 
4 individuals had prior normal levels. Blue = decreased expression. Brown = increased expression. 
It can be seen that vitamin D responsiveness equalised between the two sets of individuals after 
supplementation. From Hossain-nezhad et al [28] with permission.
Table 1:
Associations between COVID-19 mortality by country, latitude, and % of population ≥65 years 
(from [3], data accessed 18th May 2020).
Variable Regression 
coefficient
Standard 
error
p-value % of 
variation 
explained
Effect size (95% 
CI) **
Univariate 
models
Latitude 0.1074 0.0142 <0.0005 33.1 11.3%
(8.3%-14.5%)
% ≥ 65 0.1766 0.0199 <0.0005 40.4 19.3%
(14.8%-24.1%)
Multivariate 
modelA
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Latitude 0.0428 0.0196 0.031 4.4% 
(0.4%-8.5%)
% ≥ 65 0.1281 0.0291 <0.0005 43.0 13.7% 
(7.4%-20.3%)
Table 2:
Associations between vitamin D status and demographic variables associated with Covid-19 
mortality
Author/year Demographic 
variable
Type of 
study/Location
n Findings Conclusions
Kunutsor et al
2013 80
Hypertension Meta-analysis 283,537 Relative risk 
for 
hypertension 
reduced by 
Inverse 
correlation 
between vitamin 
D status and A
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0.88 (95%CI 
0.81-0.97) 
per 10ng/ml 
increment in 
Vitamin D 
levels
hypertension
Mauss et al
2015 81
Diabetes Cross-sectional
(Germany)
1821 Vit D 
<10ng/ml 
associated 
with 
increasing 
HbA1c 
P</=0.001
And Type 2 
diabetes OR 
2.55 (95%CI 
1.16-5.12)
Strong inverse 
correlation 
between vitamin 
D status, fasting 
glucose, HbA1c 
and  and Type 2 
Diabetes 
Yao et al 2015 
82
Obesity Meta-analysis 13,209 Vitamin D 
deficiency 
(varying 
definitions) 
OR 3.43 
(95% CI 2.33 
-5.06) for 
obesity
Strong inverse 
correlation 
between vitamin 
D status and 
obesity
Herrick et al
2019 83
Ethnicity Cohort study
(USA)
16,180 Prevalence of 
vitamin D 
deficiency 
(<30nmol/l)
17.5% 
(95%CI 15.2-
20.0) in non-
Hispanic 
black; 2.1% 
(95%CI 1.5-
2.7) in non-
Hispanic 
white
Strong 
association 
between 
ethnicity and 
vitamin D 
deficiency.   No 
gender 
difference
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Table 3. Trials of vitamin D in COVID-19 registered on clintrials.gov (5 June 2020)
Clinical Trial 
number
Title Location Subjects Intervention Proposed 
sample 
size
Primary 
Outcome 
Measure
Estimated 
primary 
completion
NCT04411446 Cholecalciferol to 
improve the 
outcomes of 
COVID-19 
patients 
(CARED)
Argentina Non-severe, 
symptomatic 
and 
hospitalised
Single oral dose of 
500, 000IU oral 
vitD3 vs placebo
1265 Need for 
respiratory 
support and 
change in 
respiratory 
SOFA* score
Dec 2020
NCT04407286 Vitamin D testing 
and treatment for 
COVID-19
Arizona
USA
Non-severe 
symptomatic 
patients with 
low levels of 
vitamin D
Open label 
cholecalciferol 10, 
000 IU/d bd (age 
18-69 years) or 15, 
000 IU/d tds (age 
70+) for 2 weeks. 
Continue after 2 
weeks at this dose if 
deficient. If 
insufficient after 2 
weeks, 5000 IU/day
100 Normalisation 
of vitamin D 
levels and 
change in 
severity of 
COVID-19 
symptoms from 
baseline to 2 
weeks
Aug 2020
NCT04395768 International 
ALLIANCE study 
of therapies to 
prevent 
progression of 
COVID-19
Australia Symptomatic 
COVID-19
Multiple treatments 
including 
hydroxychloroquine, 
azithromycin, zinc, 
vitamin D3 5000 IU 
daily for 14 days, 
vitamin B12 with or 
without vitamin C
200 Change in 
severity and 
duration of 
symptoms, 
length of 
hospital stay 
and need for 
mechanical 
ventilation or 
mortality within 
15 days
May 2021
NCT04386850 Oral 25-
hydroxyvitamin 
D3 and COVID-
19
Tehran, 
Iran
Symptomatic 
COVID-19
Oral 25-hydroxy 
vitamin D3 25mcg 
od for 2 months
1500 Hospitalisation, 
disease 
duration, death 
and need for 
oxygen support
Nov 2020
NCT04386850 Oral 25-
hydroxyvitamin 
D3 and COVID-
19
Tehran, 
Iran
Health care 
provider or a 
close patient 
relative with a 
negative 
Oral 25-hydroxy 
vitamin D3 25mcg 
od for 2 months
1500 Diagnosis of 
COVID-19 
infection of any 
severity, 
hospitalisation, 
Nov 2020
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COVID-19 test 
living with 
COVID-19 
positive patients 
disease 
duration, death 
and need for 
oxygen support
NCT04385940 Vitamin D and 
COVID-19 
management
Alberta
USA
Non-severe. 
symptomatic 
patients
Daily low dose 
(1000 IU/d) 
compared to weekly 
high dose 
(Ergocalciferol 50, 
000 IU twice during 
first week and one 
dose over second 
and third week
64 Symptom 
recovery (time 
from 
intervention to 
day 21)
Aug 2020
NCT04366908 Prevention and 
treatment with 
calcifediol of 
COVID-19 
coronavirus-
induced Acute 
Respiratory 
Syndrome 
(SARS)
Cordoba, 
Spain
18-90
COVID-19 pcr 
diagnosis
Best available 
therapy (BAT) plus 
Calcifediol 266 
micrograms x2 on 
day 1, then x1 on 
days 3,7,14,21,28 
vs BAT 
1008 Admission to 
ITU or death by 
day 28
July 2020
NCT04363840 The LEAD 
COVID-19 trial: 
Low risk, early 
aspirin and 
vitamin D to 
reduce COVID-
19 
hospitalisations
New 
Orleans
USA
COVID-19 
diagnosis 
<24h
50,000IU VitD3 
oral 
Once weekly x2 
plus aspirin 81mg 
od (both arms)
1080 Hospitalisatio
n within 2 
weeks
Dec 2020
 NCT04351490 Impact of zinc 
and vitamin D3 
supplementatio
n on the 
survival of 
institutionalised 
patients 
infected with 
COVID-19
Lille,
France
>60 
institutionalise
d
Zinc gluconate 
15mgs x2/day
VitD 2000IU/day 
for 2 months vs 
usual care
3140 Survival 
2months
July 2020
NCT04344041 COVID-19 and Angers, High risk ≥70y Vit D 400,000 IU 260 All cause July 2020A
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vitamin D 
supplementatio
n: a multicentre 
randomised 
trial of high 
dose versus 
standard dose 
vitamin D3 in 
high risk 
COVID-19 
patients 
(CoVitTrial)
France diagnosed 
within 48h
single dose 
versus Vit D 
50,000 IU single 
dose
mortality 14d
NCT04334005 Vitamin D on 
prevention and 
treatment of 
COVID-19
Granada 
Spain
Non-severe 
symptomatic
Single dose
25,000IU oral 
vitD3 vs usual 
care
200 All-cause 
mortality
June 2020
*SOFA-sequential organ failure assessment score
#NCT04386850 has two cohorts: a treatment study for COVID-19 positive patients and a prevention study 
for health care providers (HCP) or close patient relatives living with COVID-19 positive patients
Table 4. Summary
Vitamin D deficiency as a possible factor determining COVID-19 severity
 Lower population mortality in countries South of 28 degrees N latitude where there will 
have been sufficient sunlight to maintain vitamin D levels during the past monthsA
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 Vitamin D deficiency correlates with hypertension, diabetes, obesity, ethnicity, 
institutionalisation all of which are features associated with increased risk of severe 
COVID-19
 Vitamin D moderates inflammatory cytokine response by macrophages and respiratory 
epithelial cells to pathogens including respiratory viruses
 Vitamin D’s effect on cytokines and reduced risk for experimental lung injury is likely 
mediated by its increase in ACE2:ACE ratio and consequential reduction of angiotensin II 
– highly relevant to COVID-19 since ACE2 is the SARS-CoV-2 receptor
 Vitamin D deficiency and vitamin D receptor polymorphisms are associated with 
increased risk of severe viral bronchiolitis in infants
 Vitamin D deficiency is easily prevented by supplementation which is very safe
Fig 1A
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Fig 1B
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